RC
TAK icon

RegentAtlantic Capital’s Takeda Pharmaceutical TAK Stock Holding History

RegentAtlantic Capital’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-15,966
Closed -$242K – 486
2020
Q1 		$242K Sell
15,966
-2,558
-14% -$46.4K 0.02% 367
2019
Q4 		$365K Sell
18,524
-24,347
-57% -$466K 0.02% 353
2019
Q3 		$737K Sell
42,871
-25,130
-37% -$435K 0.05% 258
2019
Q2 		$1.2M Sell
68,001
-14,522
-18% -$264K 0.08% 210
2019
Q1 		$1.68M Buy
+82,523
New +$1.66M 0.12% 175

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

RegentAtlantic Capital's TAK Position: Q2 2020 in Review

RegentAtlantic Capital sold out of Takeda Pharmaceutical (TAK) in Q2 2020, closing a stake of 15,966 shares — an estimated $242K sold.

RegentAtlantic Capital first reported a position in TAK in Q1 2019 and held it in 5 quarters. The position peaked at $1.68M in Q1 2019. 308 funds tracked by Wall St. Rank hold TAK as of Q2 2020.

  • RegentAtlantic Capital reported no remaining Takeda Pharmaceutical position as of Q2 2020 after selling out during the quarter.
  • RegentAtlantic Capital sold 15,966 Takeda Pharmaceutical shares in Q2 2020, an estimated $242K.
  • RegentAtlantic Capital first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 5 quarters.
  • RegentAtlantic Capital's Takeda Pharmaceutical position peaked at $1.68M in Q1 2019.
  • 308 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2020.

Based on RegentAtlantic Capital's 13F filing for Q2 2020, filed 13 Aug 2020.